There’s no such thing as a “good” case of dengue fever; but some are worse than others, and it’s difficult to determine which patients will make a smooth recovery and which may find their condition life-threatening. Now, after scouring the gene expression of hundreds of patients infected with dengue virus—a mosquito-borne virus that can cause fever and joint pain; among other symptoms—scientists at the Stanford University School of Medicine have found a set of 20 genes that predicts who is at the highest risk of progressing to a severe form of the illness.
Anywhere from 5 to 20 percent of dengue cases will advance to severe. Currently, the standard of care boils down to watching and waiting; To diagnose severe dengue, doctors wait to observe specific symptoms and results of laboratory tests that typically emerge in the late stages of the disease. “These practices are not nearly sensitive or accurate enough, and some patients end up admitted to the hospital unnecessarily; while others are discharged prematurely,” said Shirit Einav.
Using their newly identified set of genes as a foundation, Einav and Khatri aim to identify predictive biomarkers that can help doctors reliably gauge the likelihood of severe dengue in patients who are newly symptomatic and use that information to provide more accurate care to help guide therapeutic clinical studies and, in the future; to guide treatment decisions. A paper detailing the study’s findings will be published in Cell Reports.
Mining old data
Adept at sleuthing out new findings from old data, Khatri used five previously published papers, which reported information on about 450 individuals collectively, to identify the severe-dengue gene set. Each study catalogued groups of dengue patients; tracking the “transcriptome,” or record of gene expression, at the onset of symptoms for each case.
“The papers had data on dengue patients from multiple countries. We looked at the data and asked, ‘Irrespective of the patient’s genetic background, age and the genetics of the dengue virus itself; different regions have different forms of dengue—what is the molecular response that always shows up when you have a dengue infection?'” Khatri said. “But we weren’t comparing healthy versus infected patients; we compared those who had an uncomplicated dengue infection with those who developed severe dengue.”
Some of the genes had down-regulation to a greater extent in some patients; and less so in others; likewise, there was variability in the degree of overactivity in the overexpressed genes. “This prediction method is more of a continuum than a binary,” Khatri said. To make sense of the continuum, the researchers developed a score that accounted for this gene-expression variability; essentially evaluating the patients’ risk for severe dengue based on dips and piques of expression in these 20 genes.
The higher the score, the higher the risk of severe dengue. Then they tested their dengue-prediction method on data from three separate; previously published cohorts of dengue patients, whose transcriptome data was public; and found that the 20-gene set predicted 100 percent of the patients who developed severe dengue. Among those predicted to come down with severe dengue, 78 percent did.
Testing the test
Next, the researchers wanted to see if their predictive measure would succeed in a real-world patient population. So in partnership with the Clinical Research Center of the Valle del Lili Foundation, in Colombia, they set up a prospective cohort of 34 participants with dengue to assess the efficacy of the predictive gene markers.
“Of course, these population samples are small, and we want to confirm our findings in larger cohorts,” Khatri said in conclusion. The researchers plan to conduct larger trials as they aim to bring the evaluation into clinical use. They’re already expanding trials into Paraguay.
“With a larger cohort, there’s also an opportunity to refine the signature; we could potentially bring down the number of genes,” Einav said. “There’s no perfect test, but we have the encouragement by these numbers, and this is already performing better than the current standard of care.“
It’s likewise possible that the genes could serve as a basis for a targeted therapy for dengue, Einav said—but that’s far on the horizon. So for now, the researchers are starting to pursue the mechanisms behind these 20 genes; trying to understand why they seem to foretell the fate of dengue patients. The work is an example of Stanford Medicine’s focus on precision health; the goal of which is to anticipate and prevent disease in the healthy; and precisely diagnose and treat disease in the ill.